{"doc_id": "si-2021-0578-reg-1", "parent_doc_id": "si-2021-0578", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 578 of 2021", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2021, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 12) Regulations 2021. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2021” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 12) regulation 2021 (2) collective citation medicinal product (prescription control supply) regulation 2003 2021 includes regulation", "start_char": 626, "end_char": 916, "source_path": "downloads\\2021\\2021_0578.pdf", "extraction_method": "pdfminer", "checksum": "sha256:17f898397a3f95b8341cd333b4d61b91f3b3de37ac59b3a1a220cf447c010c80", "cross_refs": []}
{"doc_id": "si-2021-0578-reg-2", "parent_doc_id": "si-2021-0578", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 578 of 2021", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2021, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 11) Regulations 2021 (S.I. No. 558 of 2021).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 11) regulation 2021 (s.i no 558 2021)", "start_char": 916, "end_char": 1232, "source_path": "downloads\\2021\\2021_0578.pdf", "extraction_method": "pdfminer", "checksum": "sha256:17f898397a3f95b8341cd333b4d61b91f3b3de37ac59b3a1a220cf447c010c80", "cross_refs": []}
{"doc_id": "si-2021-0578-reg-3", "parent_doc_id": "si-2021-0578", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 578 of 2021", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2021, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \n\nof 2021) to the Principal Regulations is amended— \n\n(a) \n\nin column 5 of the entry for the medicinal product “Comirnaty \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)”— \n\n(i) \n\n(ii) \n\nin subparagraph (b), by inserting “(0.3ml/30micrograms)” \nafter “booster or subsequent dose”, \n\nin subparagraph (b)(ii), by substituting “5 months (but \npreferably 6 months)” for “6 months”, \n\n(iii) \n\nin subparagraph (b)(iii), by deleting “and”, \n\n(iv) \n\n(v) \n\n(vi) \n\nin subparagraph (c), by inserting “(0.3ml/30micrograms)” \nafter “booster or subsequent dose”, \n\nin subparagraph (c)(ii), by inserting “(but preferably 6 \nmonths)” after “5 months”, \n\nin subparagraph (c)(iii), by substituting “is obtained, and” \nfor “is obtained.”, and \n\n(vii) by \n\ninserting after subparagraph \n\n(c) \n\nthe \n\nfollowing \n\nsubparagraph: \n\n“(d) a booster or subsequent dose (0.3ml/30micrograms) \nmay be administered to a person who has already \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 9th November, 2021. \n\n \n \n \n \n \n \n \n\f[578] 3 \n\nreceived a primary vaccine course against Covid-19 \nlisted in this Schedule where— \n\n(i) \n\nthe person is a healthcare worker, \n\n(ii) 5 months (but preferably 6 months) or more \nhave passed since the administration of the \nsaid primary vaccine course, and \n\n(iii) \n\ninformed consent is obtained.”, and \n\n(b) \n\nin the entry for the medicinal product “COVID-19 Vaccine \nModerna dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)”— \n\n(i) \n\nin column 1, by substituting “Spikevax (previously Covid19 Vaccine Moderna)” for “Covid-19 Vaccine Moderna”, \nand \n\n(ii) \n\nin column 5— \n\n(I) \n\n(II) \n\nin subparagraph (a) by inserting “against Covid-19” \nafter “already received a primary vaccine course”, \n\nin subparagraph (a)(iv), by substituting “legal \nguardian),” for “legal guardian), and”, \n\n(III) in \n\nsubparagraph \n\n(b), \n\nby \n\n“(0.25ml/50micrograms)” \nsubsequent dose”, \n\nafter \n\ninserting \nor \n\n“booster \n\n(IV) in subparagraph (b)(ii), by substituting “5 months \n\n(but preferably 6 months)” for “6 months”, \n\n(V) \n\nin subparagraph (b)(iii), by substituting “is obtained, \nand” for “is obtained.”, and \n\n(VI) by inserting after subparagraph (b) the following \n\nsubparagraphs: \n\n“(c) a \n\nor \n\nbooster \n\nsubsequent \n\ndose \n(0.25ml/50micrograms) may be administered \nto a person who has already received a primary \nvaccine course against Covid-19 listed in this \nSchedule where— \n\n(i) \n\nthe person is between 60 and 79 years of \nage, \n\n(ii) 5 months (but preferably 6 months) or \nsince \nthe \nthe said primary \n\nmore \nadministration of \nvaccine course, and \n\npassed \n\nhave \n\n(iii) \n\ninformed consent is obtained, and \n\n(d) \n\nbooster \n\na \ndose \n(0.25ml/50micrograms) may be administered \nto a person who has already received a primary \n\nsubsequent \n\nor \n\n \n\f4 [578] \n\nvaccine course against Covid-19 listed in this \nSchedule where— \n\n(i) \n\nthe person is a healthcare worker, \n\n(ii) 5 months (but preferably six months) or \nthe \nsince \nthe said primary \n\nmore \nadministration of \nvaccine course, and \n\npassed \n\nhave \n\n(iii) \n\ninformed consent is obtained.”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2021) principal regulation amended-- (a) column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) -- (i) (ii) subparagraph (b) inserting (0.3ml 30micrograms) booster subsequent dose subparagraph (b)(ii) substituting 5 month (but preferably 6 months) 6 month (iii) subparagraph (b)(iii) deleting (iv) (v) (vi) subparagraph (c) inserting (0.3ml 30micrograms) booster subsequent dose subparagraph (c)(ii) inserting (but preferably 6 months) 5 month subparagraph (c)(iii) substituting obtained obtained (vii) inserting subparagraph (c) following subparagraph (d) booster subsequent dose (0.3ml 30micrograms) may administered person already notice making statutory instrument published iris oifigiuil 9th november 2021 578 3 received primary vaccine course covid-19 listed schedule where-- (i) person healthcare worker (ii) 5 month (but preferably 6 months) passed since administration said primary vaccine course (iii) informed consent obtained (b) entry medicinal product covid-19 vaccine moderna dispersion injection covid-19 mrna vaccine (nucleoside modified) -- (i) column 1 substituting spikevax (previously covid19 vaccine moderna) covid-19 vaccine moderna (ii) column 5-- (i) (ii) subparagraph (a) inserting covid-19 already received primary vaccine course subparagraph (a)(iv) substituting legal guardian) legal guardian) (iii) subparagraph (b) (0.25ml 50micrograms) subsequent dose inserting booster (iv) subparagraph (b)(ii) substituting 5 month (but preferably 6 months) 6 month (v) subparagraph (b)(iii) substituting obtained obtained (vi) inserting subparagraph (b) following subparagraphs (c) booster subsequent dose (0.25ml 50micrograms) may administered person already received primary vaccine course covid-19 listed schedule where-- (i) person 60 79 year age (ii) 5 month (but preferably 6 months) since said primary administration vaccine course passed (iii) informed consent obtained (d) booster dose (0.25ml 50micrograms) may administered person already received primary subsequent 4 578 vaccine course covid-19 listed schedule where-- (i) person healthcare worker (ii) 5 month (but preferably six months) since said primary administration vaccine course passed (iii) informed consent obtained", "start_char": 1232, "end_char": 4458, "source_path": "downloads\\2021\\2021_0578.pdf", "extraction_method": "pdfminer", "checksum": "sha256:17f898397a3f95b8341cd333b4d61b91f3b3de37ac59b3a1a220cf447c010c80", "cross_refs": []}
{"doc_id": "si-2021-0578-reg-4", "parent_doc_id": "si-2021-0578", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 578 of 2021", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2021, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\n2021) to the Principal Regulations is amended— \n\n(a) \n\nin column 5 of the entry for the medicinal product “Comirnaty \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)”— \n\n(i) \n\n(ii) \n\nin subparagraph (b), by inserting “(0.3ml/30micrograms)” \nafter “booster or subsequent dose”, \n\nin subparagraph (b)(ii), by substituting “5 months (but \npreferably 6 months)” for “6 months”, \n\n(iii) \n\nin subparagraph (b)(iii), by deleting “and”, \n\n(iv) \n\n(v) \n\n(vi) \n\nin subparagraph (c), by inserting “(0.3ml/30micrograms)” \nafter “booster or subsequent dose”, \n\nin subparagraph (c)(ii), by inserting “(but preferably 6 \nmonths)” after “5 months”, \n\nin subparagraph (c)(iii), by substituting “is obtained, and” \nfor “is obtained.”, and \n\n(vii) by \n\ninserting after subparagraph \n\n(c) \n\nthe \n\nfollowing \n\nsubparagraph: \n\n“(d) a booster or subsequent dose (0.3ml/30micrograms) \nmay be administered to a person who has already \nreceived a primary vaccine course against Covid-19 \nlisted in this Schedule where— \n\n(i) \n\nthe person is a healthcare worker, \n\n(ii) 5 months (but preferably 6 months) or more \nhave passed since the administration of the \nsaid primary vaccine course, and \n\n(iii) \n\ninformed consent is obtained.”, and \n\n(b) \n\nin the entry for the medicinal product “COVID-19 Vaccine \nModerna dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)”— \n\n(i) \n\nin column 1, by substituting “Spikevax (previously Covid19 Vaccine Moderna)” for “Covid-19 Vaccine Moderna”, \nand \n\n \n \n\f[578] 5 \n\n(ii) \n\nin column 5— \n\n(I) \n\n(II) \n\nin subparagraph (a) by inserting “against Covid-19” \nafter “already received a primary vaccine course”, \n\nin subparagraph (a)(iv), by substituting “legal \nguardian),” for “legal guardian), and”, \n\n(III) in \n\nsubparagraph \n\n(b), \n\nby \n\n“(0.25ml/50micrograms)” \nsubsequent dose”, \n\nafter \n\ninserting \nor \n\n“booster \n\n(IV) in subparagraph (b)(ii), by substituting “5 months \n\n(but preferably 6 months)” for “6 months”, \n\n(V) \n\nin subparagraph (b)(iii), by substituting “is obtained, \nand” for “is obtained.”, and \n\n(VI) by inserting after subparagraph (b) the following \n\nsubparagraphs: \n\n“(c) a \n\nor \n\nbooster \n\nsubsequent \n\ndose \n(0.25ml/50micrograms) may be administered \nto a person who has already received a primary \nvaccine course against Covid-19 listed in this \nSchedule where— \n\n(i) \n\nthe person is between 60 and 79 years of \nage, \n\n(ii) 5 months (but preferably 6 months) or \nsince \nthe \nthe said primary \n\nmore \nadministration of \nvaccine course, and \n\npassed \n\nhave \n\n(iii) \n\ninformed consent is obtained, and \n\n(d) \n\nor \n\nbooster \n\nsubsequent \n\na \ndose \n(0.25ml/50micrograms) may be administered \nto a person who has already received a primary \nvaccine course against Covid-19 listed in this \nSchedule where— \n\n(i) \n\nthe person is a healthcare worker, \n\n(ii) 5 months (but preferably 6 months) or \nsince \nthe \nthe said primary \n\nmore \nadministration of \nvaccine course, and \n\npassed \n\nhave \n\n(iii) \n\ninformed consent is obtained.”. \n\n \n \n \n \n \n \n\f6 [578] \n\nGIVEN under the Official Seal of the Minister for Health, \n\n5 November, 2021. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[578] 7", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2021) principal regulation amended-- (a) column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) -- (i) (ii) subparagraph (b) inserting (0.3ml 30micrograms) booster subsequent dose subparagraph (b)(ii) substituting 5 month (but preferably 6 months) 6 month (iii) subparagraph (b)(iii) deleting (iv) (v) (vi) subparagraph (c) inserting (0.3ml 30micrograms) booster subsequent dose subparagraph (c)(ii) inserting (but preferably 6 months) 5 month subparagraph (c)(iii) substituting obtained obtained (vii) inserting subparagraph (c) following subparagraph (d) booster subsequent dose (0.3ml 30micrograms) may administered person already received primary vaccine course covid-19 listed schedule where-- (i) person healthcare worker (ii) 5 month (but preferably 6 months) passed since administration said primary vaccine course (iii) informed consent obtained (b) entry medicinal product covid-19 vaccine moderna dispersion injection covid-19 mrna vaccine (nucleoside modified) -- (i) column 1 substituting spikevax (previously covid19 vaccine moderna) covid-19 vaccine moderna 578 5 (ii) column 5-- (i) (ii) subparagraph (a) inserting covid-19 already received primary vaccine course subparagraph (a)(iv) substituting legal guardian) legal guardian) (iii) subparagraph (b) (0.25ml 50micrograms) subsequent dose inserting booster (iv) subparagraph (b)(ii) substituting 5 month (but preferably 6 months) 6 month (v) subparagraph (b)(iii) substituting obtained obtained (vi) inserting subparagraph (b) following subparagraphs (c) booster subsequent dose (0.25ml 50micrograms) may administered person already received primary vaccine course covid-19 listed schedule where-- (i) person 60 79 year age (ii) 5 month (but preferably 6 months) since said primary administration vaccine course passed (iii) informed consent obtained (d) booster subsequent dose (0.25ml 50micrograms) may administered person already received primary vaccine course covid-19 listed schedule where-- (i) person healthcare worker (ii) 5 month (but preferably 6 months) since said primary administration vaccine course passed (iii) informed consent obtained  6 578 given official seal minister health 5 november 2021 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 578 7", "start_char": 4458, "end_char": 7838, "source_path": "downloads\\2021\\2021_0578.pdf", "extraction_method": "pdfminer", "checksum": "sha256:17f898397a3f95b8341cd333b4d61b91f3b3de37ac59b3a1a220cf447c010c80", "cross_refs": []}
{"doc_id": "si-2021-0578-explanatory-note", "parent_doc_id": "si-2021-0578", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 578 of 2021", "title": "Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to allow booster/subsequent doses of the \nCominarty and Spikevax COVID-19 vaccines to be supplied and administered \nto certain persons. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 12) Regulations 2021. \n\n \n \n \n \n \n \n \n \n\f8 [578] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-322) 75. 11/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation allow booster subsequent dos cominarty spikevax covid-19 vaccine supplied administered certain person regulation may cited medicinal product (prescription control supply) (amendment) (no 12) regulation 2021 8 578 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.00 (dh-322) 75 11 21 propylon", "start_char": 7838, "end_char": 8878, "source_path": "downloads\\2021\\2021_0578.pdf", "extraction_method": "pdfminer", "checksum": "sha256:17f898397a3f95b8341cd333b4d61b91f3b3de37ac59b3a1a220cf447c010c80", "cross_refs": []}
